News Release

First bioavailable compound that specifically inhibits free radical production in mitochondria prevents and treats metabolic syndrome in mice

A potential therapeutic for one of the major chronic diseases of aging

Peer-Reviewed Publication

Buck Institute for Research on Aging

Mopping up free radicals with antioxidants was the rage in the 1970s; people were taking large, sometimes massive doses of various general antioxidants, including vitamins and minerals, to try to remove harmful byproducts of energy metabolism. The method was supposed to blunt the effects of aging and stave off chronic disease. The strategy didn’t work, and in some cases, it caused harm because untargeted antioxidants also compromised beneficial cellular signaling pathways. Over time, this area of research went on the shelf as mitochondrial theories of disease and aging fell into disfavor.

But research at the Buck offers a new way to deal with free radicals: rather than mop them up, take a pill that selectively keeps them from being produced in the first place. Building on this work, collaborative research between the Buck and Calico Labs, recently published in Free Radical Biology and Medicine shows that specifically inhibiting free radical production at a particular mitochondrial site prevents and treats metabolic syndrome in mice, by preventing and reversing insulin resistance.

We think that mitochondrial radical production drives many chronic diseases of aging, and  that blocking the production of free radicals is a viable disease-treating and anti-aging intervention,” said Martin Brand, Ph.D., Buck Professor Emeritus and senior investigator of the study. Weve found a way to selectively keep problematic free radicals in check without compromising normal energy production in the mitochondria. These compounds act like a cork in a wine bottle. They plug a specific site so that it doesnt produce free radicals, without hindering the mitochondria’s critical function of energy metabolism.  We look forward to continuing this groundbreaking area of research.”

The orally bioavailable compound that has been developed, S1QEL1.719 (a new “S1QEL” - Suppressor of site IQ Electron Leak), was given both prophylactically and therapeutically to mice fed a high-fat diet that causes metabolic syndrome. Treatment decreased fat accumulation, strongly protected against decreased glucose tolerance and prevented or reversed the increase in fasting insulin levels by protecting against the development of insulin resistance.  

Acting on mitochondrial complex I highlights potential interventions for other conditions

S1QEL1s act on site IQ in mitochondrial complex I. (The mitochondrial electron transport chain consists of four protein complexes integrated into the inner mitochondrial membrane. Together they carry out a multi-step process, oxidative phosphorylation, through which cells derive 90% of their energy.) 

First author and Buck staff scientist Mark Watson, Ph.D., says current literature strongly implicates complex I in a number of different diseases, from metabolic syndrome to Alzheimers, fatty liver disease, and noise-induced hearing loss, as well as the underlying aging process itself.

 “S1QELs don’t sequester oxidants or radicals. Rather, they specifically inhibit radical production at the IQ site on complex I without interfering with other sites,” Watson said. So the normal redox signaling that we require in our cells will continue. S1QELs just modulate that one site. They are very clean, very specific, and do not disrupt mitochondrial functioning like inhibitors of mitochondria do.

Brand says the data shows that free radical production from complex I is an essential driver of insulin resistance and metabolic syndrome, a major disease of poor lifestyle choices and of aging. He says this feature is a strong reason to revisit the mitochondrial theory of aging. These compounds fine-tune mitochondrial production of free radicals,” he said. And its really interesting; just inhibiting this specific site improves the whole redox environment and prevents metabolic disease, and that is amazing.”

Citation: Suppression of superoxide/hydrogen peroxide production at mitochondrial site IQ decreases fat accumulation, improves glucose tolerance and normalizes fasting insulin concentration in mice fed a high-fat diet


Other Buck researchers involved in the study include Harmanmeet Brar, Edwin T. Gibbs II, Hoi-Shan Wong, and Pratiksha A. Dighe. Collaborators from AbbVie include Bryan McKibben, Stephan Riedmaier, Amy Siu, James S. Polakowski, Jason A. Segreti, Xiaoquin Liu, Seung Won Chung, Y. Marina Pliushchev, Nathan Gesmundo, Zhi Wang, and Timothy A. Vortherms.

Acknowledgements: The research was supported by Calico Life Sciences, LLC, South San Francisco, CA

About the Buck Institute for Research on Aging

At the Buck, we aim to end the threat of age-related diseases for this and future generations. We bring together the most capable and passionate scientists from a broad range of disciplines to study mechanisms of aging and to identify therapeutics that slow down aging. Our goal is to increase human health span, or the healthy years of life. Located just north of San Francisco, we are globally recognized as the pioneer and leader in efforts to target aging, the number one risk factor for serious diseases including Alzheimers, Parkinsons, cancer, macular degeneration, heart disease, and diabetes. The Buck wants to help people live better longer. Our success will ultimately change healthcare. Learn more at:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.